<DOC>
	<DOCNO>NCT02039258</DOCNO>
	<brief_summary>The purpose study assess effect coadministration high-fat meal oral bioavailability fix dose combination Canagliflozin/extended release Metformin ( CANA/MET XR ) tablet , contain 150 mg CANA 1,000 mg extend release MET healthy participant .</brief_summary>
	<brief_title>Pharmacokinetics Fixed Dose Combination Canagliflozin/Metformin Coadministered With Food</brief_title>
	<detailed_description>This randomize ( sequence fast fed period accompany study drug intake assign chance ) , open-label ( physicians participant know identity assign treatment ) , single-center , single-dose , 2-period , 2-sequence , crossover study Canagliflozin/extended release Metformin ( CANA/MET XR ) fix dose combination ( FDC ) tablet 150 mg/1,000 mg . Approximately 24 healthy adult participant enrol ensure least 20 complete study . After screen period , participant randomly assign 1 2 treatment sequence ( AB BA ) Day 1 Period 1 . Treatment A mean participant receive single 150/1,000 mg CANA/MET XR FDC tablet fast condition , Treatment B mean participant receive drug feed condition . Participants need remain study center 4 day ( 72 hour postdose ) drug administration collection blood sample treatment period . There 10- 14-day washout period Period 1 Period 2 . On Day 4 ( 72 hour postdose ) Period 2 , participant discharge study center , give instruction return follow-up visit 7 10 day later . For Treatment B ( fed state ) , participant provide standardized high-fat breakfast . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must sign inform consent document indicate understand purpose study procedure Must body mass index ( BMI ) 18 30 kg/m² , inclusive Must body weight less 50 kg Must blood pressure 90 140 mmHg inclusive , systolic , high 90 mmHg diastolic screen Must normal renal function evidence kidney damage ( include abnormality blood urine test ) History current clinically significant medical illness Use prescription nonprescription medication ( include vitamin herbal supplement ) History clinically significant allergy , especially know hypersensitivity intolerance lactose Known allergy heparin history heparin induce thrombocytopenia History smoking use nicotinecontaining substance within previous 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin</keyword>
	<keyword>INVOKANA®</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>